Determination Method for Steroid 5α-Reductase Activity Using Liquid Chromatography/Atmospheric Pressure Chemical Ionization–Mass Spectrometry

October 2005 in “ Analytical Sciences ”

Kuniko Mitamura, Chie Ogasawara, Asami Shiozawa, Erika Terayama, Kazutake Shimada

steroid 5α-reductase 5α-dihydrotestosterone 5α-androstane-3α,17β-diol Finasteride liquid chromatography atmospheric pressure chemical ionization mass spectrometry Propecia

Studysummary This study developed a method using LC/APCI-MS to measure the activity of steroid 5α-reductase, applied to kinetic studies and inhibitory tests with Finasteride in a rat prostatic enzyme model.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on kanazawa-u.repo.nii.ac.jp →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

research Dihydrotestosterone and the Concept of 5-Alpha-Reductase Inhibition in Human Benign Prostatic Hyperplasia

184 citations , January 2000 in “European Urology”

This abstract reviews the role of finasteride and potential dual 5alpha-reductase inhibitors in treating benign prostatic hyperplasia, suggesting that dual inhibitors may offer greater DHT suppression and therapeutic advantages, while emphasizing the need for clinical evaluation.

research FCE 28260, A New 5α-Reductase Inhibitor: In Vitro and In Vivo Effects

17 citations , June 1996 in “The Journal of Steroid Biochemistry and Molecular Biology”

In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.

research Species Differences in Prostatic Steroid 5α-Reductases of Rat, Dog, and Human

193 citations , August 1985 in “Endocrinology”

This study found significant species differences in the enzyme activity and inhibitor affinities of prostatic 5α-reductases from rats, dogs, and humans, with variable potencies for different 3-oxo-4-azasteroid inhibitors across species.